LUND, Sweden, Nov. 16, 2022 /PRNewswire/ -- Immunovia AB
(NASDAQ: IMMNOV) announces today that Philipp Mathieu, CEO of Immunovia, has purchased
150000 warrants of the 2022/2026 scheme for approximately 297
KSEK.
His total holding now amounts to 2108 shares and 250 000
warrants in Immunovia. The warrants have a subscription price per
share of SEK 88.69. Other management
team members have subscribed for 100 000 warrants of the same
scheme.
For more information, please contact:
Karin Almqvist Liwendahl
CFO
kain.almqvist.liwendahl@immunovia.com
+46 70 911 56 08
About Immunovia
Immunovia AB is a diagnostic company with the vision to
revolutionize blood-based diagnostics and increase survival rates
for patients with cancer.
Our first product, IMMray™ PanCan-d is the only blood test
currently available for early detection of pancreatic cancer. The
test has unmatched clinical performance. Commercialization of
IMMray™ PanCan-d started in August
2021 in the USA and IMMray™
PanCan-d is offered as a laboratory developed test (LDT)
exclusively through Immunovia, Inc. For more information see:
www.immunoviainc.com.
Immunovia collaborates and engages with healthcare providers,
leading experts and patient advocacy groups globally to make this
test available to all high-risk pancreatic cancer groups.
The USA, the first market in
which IMMray™ PanCan-d is commercially available, is the world's
largest market for the detection of pancreatic cancer with an
estimated value of more than USD 4
billion annually.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com.
The following files are available for download:
|
https://mb.cision.com/Main/13121/3667828/1673636.pdf
|
Press release
(PDF)
|
View original
content:https://www.prnewswire.co.uk/news-releases/chief-executive-offier-philipp-mathieu-buys-immunovia-warrants-301679713.html